ArticleJapanese journal of clinical oncology2022

Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy.

Makoto Yoshimitsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.